Chad Messer

- Lantern Pharma (LTRN) is advancing **three clinical-stage cancer drug candidates**: **LP-300** (Phase II, targeting a **$4-5 billion market** in non-small cell lung cancer), **LP-184** (completed Phase I, with planned Phase Ib/II trials), and **LP-284** (in trials for blood cancers, a **$3-4 billion market**).  **[1763950_tx_377949_1]** **[1763950_tx_377949_2]** **[1763950_tx_377949_3]** 
- The company maintains a disciplined fiscal profile with a burn rate of approximately **$4.5 million per quarter** and has cash projected to last into **2026**.  **[1763950_tx_377949_1]** **[1763950_tx_377949_6]** 
- Lantern Pharma has secured **11 FDA designations** (**5 orphan, 4 rare pediatric, 2 Fast Track**) and leverages its AI platform, RADAR, for drug development, holding approximately **140 issued and pending patent applications**.  **[1763950_tx_377949_1]** **[1763950_tx_377949_6]** **[1763950_tx_377949_7]** 
- The company plans to make aspects of its AI platform publicly available to drive collaborations and generate revenue through token sales.  **[1763950_tx_377949_2]** **[1763950_tx_377949_6]**